DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Phase 3

Completed

Conditions: Beta-Thalassemia

Interventions: Drug: ICL670
Drug: deferoxamine

First Posted Date: 2003-06-04

Last Posted Date: 2012-04-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 595

Registration Number: NCT00061750

Locations: 🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸
Children's Hospital Oakland, Oakland, California, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

and more 4 locations

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

Phase 2

Completed

Conditions: Beta-thalassemia
Myelodysplastic Syndromes
Fanconi Syndrome
Anemia, Aplastic
Anemia, Diamond-Blackfan

First Posted Date: 2003-06-04

Last Posted Date: 2017-08-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 175

Registration Number: NCT00061763

Locations: 🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 3 locations

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Neoplasms
Rectal Neoplasms
Colonic Neoplasms

Interventions: Drug: Vatalanib

First Posted Date: 2003-03-14

Last Posted Date: 2017-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 855

Registration Number: NCT00056446

Locations: 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸
Owensboro Medical Health System, Owensboro, Kentucky, United States
🇺🇸
Columbus CCOP, Columbus, Ohio, United States

and more 140 locations

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Phase 2

Completed

Conditions: Von Hippel-Lindau Disease
Retinal Hemangioblastoma
CNS Hemangioblastoma

Interventions: Drug: PTK787/ZK 222584

First Posted Date: 2003-01-22

Last Posted Date: 2017-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 11

Registration Number: NCT00052013

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

Phase 3

Completed

Conditions: Paget's Disease of Bone

Interventions: Drug: Zoledronic Acid
Drug: Risedronate
Drug: Placebo to Risedronate
Drug: Placebo to Zoledronic Acid
Dietary Supplement: Calcium and Vitamin D

First Posted Date: 2003-01-15

Last Posted Date: 2012-05-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 172

Registration Number: NCT00051636

Locations: 🇬🇧
Novartis Investigative Site, Vale of Glamorgan, United Kingdom
🇬🇧
Novartis investigative site, Pernarth, United Kingdom
🇬🇧
Novartis Investigative site, Penarth, United Kingdom

Pediatric Epilepsy Study

Phase 3

Completed

Conditions: Epilepsy
Epilepsies, Partial

First Posted Date: 2003-01-01

Last Posted Date: 2011-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 132

Registration Number: NCT00050934

Locations: 🇲🇽
Novartis, Mexico City, Mexico
🇧🇷
Brigadeiro Hospital, Sao Paulo - SP, Brazil

Pediatric Epilepsy Study

Phase 3

Completed

Conditions: Epilepsy

First Posted Date: 2003-01-01

Last Posted Date: 2011-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 94

Registration Number: NCT00050947

Locations: 🇲🇽
Novartis, Mexico City, Mexico
🇧🇷
Brigadeiro Hospital, Sao Paulo - SP, Brazil

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Phase 4

Completed

Conditions: Neoplasms
Diarrhea

First Posted Date: 2002-12-18

Last Posted Date: 2009-11-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT00050635

Locations: 🇺🇸
Creticos Cancer Center, Chicago, Illinois, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Oncology Hematology Group of South Florida, Miami, Florida, United States

and more 30 locations

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Phase 2

Completed

Conditions: Carcinoid
Neuroendocrine Tumors

Interventions: Drug: EPO906 epothilone B

First Posted Date: 2002-12-05

Last Posted Date: 2017-03-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT00050349

Locations: 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2), New Orleans, Louisiana, United States
🇺🇸
University of Iowa Health Care, Iowa City, Iowa, United States

and more 2 locations

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Phase 3

Completed

Conditions: Breast Neoplasms
Osteoporosis

Interventions: Drug: Zoledronic Acid
Drug: Letrozole

First Posted Date: 2002-11-20

Last Posted Date: 2014-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 602

Registration Number: NCT00050011

Locations: 🇺🇸
FL Community Cancer Center, Brooksville, Florida, United States
🇺🇸
Eastern Connecticut Hematology/Oncology Associates, Norwich, Connecticut, United States
🇺🇸
Elmhurst Memorial Hospital, Elhurst, Illinois, United States

and more 41 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy